Thermo-sensitively and magnetically ordered mesoporous carbon nanospheres for targeted controlled drug release and hyperthermia application

Design, Synthesis, and Anti-Breast Cancer Potential of Imidazole-Pyridine Hybrid Molecules In Vitro and Ehrlich Ascites Carcinoma Growth Inhibitory Activity Assessment In Vivo

Breast cancer remains a challenging medical issue and is a high priority for biomedical research despite significant advancements in cancer research and therapy. The current study aims to determine the anticancer activity of a group of imidazole-pyridine-based scaffolds against a variety of breast cancer cell lines differing in their receptor expression (estrogen receptor (ER), progesterone receptor (PR), and HER-2). A series of 10 molecules (coded 5a-5j) were synthesized through multicomponent and alkylation reactions. FTIR, MS, 1H, and 13C NMR spectral analyses confirmed the structures and purity of the synthesized molecules. Subsequently, these molecules were tested for their ability to inhibit the viability of cell lines representing carcinoma of the breast, viz., MDA-MB-468 (ER-, PR-, and HER-), BT-474 (ER+, PR+, and HER+), T-47D (ER+, PR+, and HER-), and MCF-7 (ER+, PR+, and HER-) in vitro. Among these 10 molecules, 5a, 5c, 5d, and 5e exhibited better potency, as evidenced by IC50 < 50 μM at 24 h of treatment against BT-474 and MDA-MB-468 cell lines. However, except for 5d, the IC50 value is much higher than 50 μM when tested against T47D and MCF-7 cell lines at 24h. Extended treatment for 48 h reduced the effect of these molecules, as an increase in IC50 was observed. In mice, intraperitoneal administration of 5e retarded the Ehrlich ascites carcinoma (EAC) growth without causing any organ toxicity at the doses tested. In summary, we report the synthesis scheme and key structural requirements for a new series of imidazole-pyridine molecules for in vitro inhibition of the feasibility of breast cancer cells and in vivo inhibition of EAC tumors.

Near-Infrared-Enpowered Nanomotor-Mediated Targeted Chemotherapy and Mitochondrial Phototherapy to Boost Systematic Antitumor Immunity

Phototherapy is an important strategy to inhibit tumor growth and activate antitumor immunity. However, the effect of photothermal/photodynamic therapy (PTT/PDT) is restricted by limited tumor penetration depth and unsatisfactory potentiation of antitumor immunity. Here, a near-infrared (NIR)-driven nanomotor is constructed with a mesoporous silicon nanoparticle (MSN) as the core, end-capped with Antheraea pernyi silk fibroin (ApSF) comprising arginine-glycine-aspartate (RGD) tripeptides. Upon NIR irradiation, the resulting ApSF-coated MSNs (DIMs) loading with photosensitizers (ICG derivatives, IDs) and chemotherapeutic drugs (doxorubicin, Dox) can efficiently penetrate into the internal tumor tissues and achieve effective phototherapy. Combined with chemotherapy, a triple-modal treatment (PTT, PDT, and chemotherapy) approach is developed to induce the immunogenic cell death of tumor cells and to accelerate the release of damage-associated molecular patterns. In vivo results suggest that DIMs can promote the maturation of dendritic cells and surge the number of infiltrated immune cells. Meanwhile, DIMs can polarize macrophages from M2 to M1 phenotypes and reduce the percentages of immunosuppressive Tregs, which reverse the immunosuppressive tumor microenvironment and activate systemic antitumor immunity. By achieving synergistic effects on the tumor inhibition and the antitumor immunity activation, DIMs show great promise as new nanoplatforms to treat metastatic breast cancer.

Biomass-derived porous carbon with high drug adsorption capacity undergoes enzymatic and chemical degradation

Degradability is a key safety issue when choosing materials for biomedical applications and environmental protection. This factor greatly limits the application of porous carbon in these areas due to the inert and stable nature of carbon network. In this work, this conflict could be well-resolved by rational designing a mesoporous carbon (MC) with biomass as a carbon source. The retained oxygen-containing species simultaneously increase drug adsorption capacity and the degradability of MC. The maximum adsorption quantity for doxorubicin over MC can reach 395.3 mg/g, about 3-fold over carbon nanotubes. The detailed analysis reveals that the degradation of MC occurs via a radical mediated oxidation process. The high electron density feature of MC facilitates the electrophilic addition reaction in the presence of HO. During this process, the carbon network is gradually degraded into fragments, carbon nanodots and ultimately to CO₂. This work opens up a new way to fabricate degradable porous materials and provides a promising material for the practical application in biomedical and environmental field.

Enhanced Doxorubicin Delivery in Folate-Overexpressed Breast Cancer Cells Using Mesoporous Carbon Nanospheres

Nanoparticle-based drug delivery reveals the safety and effectiveness and avoids premature drug release from the nanocarrier. These nanoparticles improve the bioavailability and stability of the drug against chemical and enzymatic degradation and facilitate targeted drug delivery. Herein, targeted folic acid-conjugated oxidized mesoporous carbon nanospheres (Ox-MPCNPs) were successfully fabricated and developed as antitumoral doxorubicin delivery for targeted breast cancer therapy. Fourier transform infrared spectroscopy studies confirmed that the doxorubicin was successfully bound on the Ox-MPCNP through hydrogen bonding and π-π interactions. X-ray diffraction studies showed that the synthesized doxorubicin-loaded Ox-MPCNP is semi-crystalline. The surface morphology of the synthesized doxorubicin-loaded Ox-MPCNP (DOX/Ox-MPCNP-Cys-PAsp-FA) was studied by scanning electron microscopy and high-resolution transmission electron microscopy, which demonstrates a sphere-shaped morphology. The cytotoxic effects of DOX/Ox-MPCNP-Cys-PAsp-FA were studied in MCF-7 breast cancer cells using the CytoTox96 assay kit. The study confirmed the cytotoxic effects of the synthesized nanospheres in vitro. Moreover, DOX/Ox-MPCNP-Cys-PAsp-FA-treated cells displayed efficient cell apoptosis and cell death in flow cytometry analysis. The mitochondrial fragmentation and nucleus damages were further confirmed by fluorescence microscopy. Thus, the approach used to construct the DOX/Ox-MPCNP-Cys-PAsp-FA carrier provides excellent opportunities for the targeted treatment of breast cancer.

An updated review of mesoporous carbon as a novel drug delivery system

The nanotechnology approach has been recently adopted to provide more reliable, effective, controlled, and safe drug delivery systems. Nanostructured materials have gained great interest, including siliceous and carbonaceous nanoparticles. The effectiveness of mesoporous carbon nanoparticles (MCNs) in tumor imaging, targeting, and treatment is urging for more future studies. MCNs possess superior properties such as their biocompatibility, large surface area, large pore volume, tunability, and more responsive behavior to internal and external release triggers. These outstanding features make MCNs more applicable for stimuli-responsive drug delivery than the conventional forms of mesoporous silica nanoparticles (MSNs) and other carbon nanoparticles. In this review, we outlined the latest updates regarding the safety, benefits, and potential applications of MCNs.

A Tri-Stimuli Responsive (Maghemite/PLGA)/Chitosan Nanostructure with Promising Applications in Lung Cancer

A (core/shell)/shell nanostructure (production performance ≈ 50%, mean diameter ≈ 330 nm) was built using maghemite, PLGA, and chitosan. An extensive characterization proved the complete inclusion of the maghemite nuclei into the PLGA matrix (by nanoprecipitation solvent evaporation) and the disposition of the chitosan shell onto the nanocomposite (by coacervation). Short-term stability and the adequate magnetism of the nanocomposites were demonstrated by size and electrokinetic determinations, and by defining the first magnetization curve and the responsiveness of the colloid to a permanent magnet, respectively. Safety of the nanoparticles was postulated when considering the results from blood compatibility studies, and toxicity assays against human colonic CCD-18 fibroblasts and colon carcinoma T-84 cells. Cisplatin incorporation to the PLGA matrix generated appropriate loading values (≈15%), and a dual pH- and heat (hyperthermia)-responsive drug release behaviour (≈4.7-fold faster release at pH 5.0 and 45 °C compared to pH 7.4 and 37 °C). The half maximal inhibitory concentration of the cisplatin-loaded nanoparticles against human lung adenocarcinoma A-549 cells was ≈1.6-fold less than that of the free chemotherapeutic. Such a biocompatible and tri-stimuli responsive (maghemite/PLGA)/chitosan nanostructure may found a promising use for the effective treatment of lung cancer.

Drug Delivery Approaches for Doxorubicin in the Management of Cancers

Aim:

We aimed to review the drug delivery approaches including a novel drug delivery system of doxorubicin as an important anticancer drug.

Background:

Doxorubicin (DOX) is widely used against breast, uterine, ovarian, lung and cervical cancer. It is listed among the essential medicines by WHO and is thus a very important drug that can be used to fight against cancer. Despite its effectiveness, the use of the drug is limited due to its dose-dependent toxicity. Several studies based on the DOX have suggested the need for novel drug delivery formulations in the treatment of malignant and cancerous diseases due to its cytotoxic nature.

Objectives:

This review focuses on the different formulations of DOX which is a useful drug in the management of cancers, but associated with toxicity thus these approaches found applicability in the reduction of its toxicity.

Methods:

We searched the scientific database using cancer, DOX, and different formulations as the keywords. Here in only peer-reviewed research articles collected which were useful to our current work.

Results:

This study is based on an examination of the recent advancements of its novel drug delivery formulations. DOX hydrochloride is the first liposomal anticancer drug, administered via the intravenous route, and also clinically approved for the treatment of lymphomas, leukemias, and solid tumors. DOX is prepared into a liposomal formulation that contains polyethylene glycol (PEG) layer around DOX containing liposome made by pegylation process. DOX also formulated in nano-formulations which is also discussed herein led to reduced toxicity and increased efficacy.

Conclusion:

In the review, we described the significance of DOX in the form of different delivery approaches in the management of cancers with a reduction in the associated toxicity.

In situ embedding dual-Fe nanoparticles in synchronously generated carbon for the synergistic integration of magnetic resonance imaging and drug delivery

In situ incorporating versatile magnetic iron nanoparticles into ordered mesoporous carbon (OMC) by means of synthetic methodology for functional integration is a great challenge. Inspired by the phenomenon of uniovular twins in nature, a homometallic [Fe₉(μ₃-O)₄(O₃PPh)₃(O₂CCMe₃)₁₃] ({Fe₉P₃}) cluster was synthesized and used as the ovulum to in situ produce dual-Fe nanoparticle (γ-Fe₂O₃ and Fe(PO₃)₃)-functionalized OMC (dual-Fe/OMC). In vitro magnetic resonance imaging (MRI) studies showed a longitudinal relaxation (r ₁) and transverse relaxation (r ₂) of 9.74 and 26.59 mM^-1 s^-1 with a r ₂/r ₁ ratio of 2.73 at 0.5 T. The MRI performances were further examined by mouse model with a subcutaneous HeLa tumor. In addition, the low cytotoxicity, considerable loading capacity and delivery of doxorubicin hydrochloride (DOX) were also studied in vitro. These results demonstrate the feasibility of the concept of uniovular twins in the one-pot preparation of dual-Fe/OMC for functional integration.

pH-triggered intracellular release of doxorubicin by a poly(glycidyl methacrylate)-based double-shell magnetic nanocarrier

Two core-double-shell pH-sensitive nanocarriers were fabricated using Fe₃O₄ as magnetic core, poly(glycidyl methacrylate-PEG) and salep dialdehyde as the first and the second shell, and doxorubicin as the hydrophobic anticancer drug. Two nanocarriers were different in the drug loading steps. The interaction between the first and the second shell assumed to be pH-sensitive via acetal cross linkages. The structure of nanocarriers, organic shell loading, magnetic responsibility, morphology, size, dispersibility, and drug loading content were investigated by IR, NMR, TG, VSM, XRD, DLS, HRTEM and UV-Vis analyses. The long-term drug release profiles of both nanocarriers showed that the drug loading before cross-linking between the first and second shell led to a more pH-sensitive nanocarrier exhibiting higher control on DOX release. Cellular toxicity assay (MTT) showed that DOX-free nanocarrier is biocompatible having cell viability greater than 80% for HEK-293 and MCF-7 cell lines. Besides, high cytotoxic effect observed for drug-loaded nanocarrier on MCF-7 cancer cells. Cellular uptake analysis showed that the nanocarrier is able to transport DOX into the cytoplasm and perinuclear regions of MCF-7 cells. In vitro hemolysis and coagulation assays demonstrated high blood compatibility of nanocarrier. The results also suggested that low concentration of nanocarrier have a great potential as a contrast agent in magnetic resonance imaging (MRI).

Folic acid-conjugated magnetic ordered mesoporous carbon nanospheres for doxorubicin targeting delivery

Folic acid-conjugated magnetic ordered mesoporous carbon nanospheres (FA-MOMCNs) are developed as a targeting delivery vehicle of doxorubicin (DOX) in this work. Investigations on DOX loading mechanism show that the loading capacity of FA-MOMCNs is up to 577.12 mg g^-1 by means of both physical porous adsorption and covalent interactions, and the pH-dependent drug release is achieved. Excellent biocompatibility of FA-MOMCNs with blood and cells is confirmed by hemolysis and cytotoxicity assays. With the assistance of effective passive and active targeting, DOX-loading FA-MOMCNs can be readily internalized into cancer cell, where the carried DOX can be efficiently released in the acidic microenvironment of the cancer cell for its proliferation inhibition. This controlled release and targeting vehicle of DOX makes it possible to reduce the toxic effect to normal tissues during circulation in the body and is promising for highly efficient chemotherapy.

Phytosynthesis of nearly monodisperse CuO nanospheres using Phyllanthus reticulatus/Conyza bonariensis and its antioxidant/antibacterial assays

In the present article we have developed an eco-friendly, phytosynthetic, cost-effective and straightforward method for the synthesis of nearly monodisperse CuO nanospheres (NSP) using leaf extracts of medicinal plants Phyllanthus reticulatus (PR) and Conyza bonariensis (CB) as novel green reducing agents. Copper nitrate (Cu (NO₃)₂) was used as a precursor. The stoichiometric ratio of both leaf extracts (PR/CB) and Cu(NO₃)₂ was standardized for the synthesis of NSP. During formation of CuO NSP, a color of solution gradually changed from light greenish-blue to black with a number of intermediate stages and it correlated to the reduction reaction catalyzed by phytochemicals. As-synthesized materials were characterized in detail at the structural, electronic level and morphological authentication by XRD, FT-IR, EDS, UV-DRS, Raman, XPS, SEM, TEM, BET and AFM. SEM studies of phytosynthesized materials revealed nearly monodisperse nanospheres, while TEM rendered average particles size 4-14 nm. Also, AFM profiles suggested a homogenized nature of the nanospheres. Then, the antioxidant property was obtained by α, α-diphenyl-β-picrylhydrazyl (DPPH). Ethanolic, methanolic extracts were used for the antioxidant activity, while ascorbic acid was used as a standard medium. Each plant extract exhibited noteworthy antioxidant activity. Moreover, the antibacterial activity of CuO NSP (PR/CB) was tested against human pathogenic bacteria viz. gram-positive Staphylococcus aureus, Klebsiella pneumoniae, and gram-negative Escherichia coli. Result rendered effective antibacterial activity against Escherichia coli.